Drug Profile
GS 2838
Latest Information Update: 22 May 2002
Price :
$50
*
At a glance
- Originator Gilead Sciences
- Class Antivirals; Nucleotides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Respiratory syncytial virus infections
Most Recent Events
- 22 May 2002 Discontinued - Preclinical for Respiratory syncytial virus infections (PO)
- 21 May 2001 Profile reviewed but no significant changes made
- 31 Aug 1998 No-Development-Reported for Respiratory syncytial virus infections (PO)